Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 3
1(50.0%)
Phase 2
1(50.0%)
2Total
Phase 3(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT06211452Phase 3Completed

Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia

Role: lead

NCT04897490Recruiting

RWE of 1st Line Treatment With ATO/ATRA for Adult APL

Role: lead

NCT05078840Unknown

PET Adapted Treatment of Patients With Limited Stage DLBCL and no Risk Factors

Role: lead

NCT05127148Recruiting

RWE of Pediatric-like Protocol for AYA Patients With Ph-negative ALL

Role: lead

NCT04776265Unknown

RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT

Role: lead

NCT05360758Unknown

Ibrutinib Adapted to Response in Patients With CLL

Role: lead

NCT05127798Unknown

RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old.

Role: lead

NCT00002499Phase 2Unknown

Combination Chemotherapy in Treating Children With Relapsed Acute Lymphocytic Leukemia

Role: lead

All 8 trials loaded